March 19, 2015 : Episode 1

Video

Phase III Ibrutinib Findings, Prostate Cancer Congress, and More

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Related Content
Prostate Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 28th 2025

Leuprolide Acetate With Enzalutamide or Placebo Is Associated With Full Testosterone Recovery in Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Prostate Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 28th 2025

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Mark D. Tyson, II, MD, MPH
April 24th 2025

Oncology Experts Preview Top Abstracts From AUA 2025

Evan Y. Yu, MD, of Fred Hutchinson Cancer Center
April 22nd 2025

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC